 
 |
6/1/2002 Bob Buderi — MIT Technology Review
MIT Technology Review: Myhrvold's Exponential Economy
Microsoft's former technology chief is branching out. He's looking for industries where efficiencies multiply every couple of years—in infotech, sure, but biology too.
| 5/1/2002 John Dodge — Bio-IT World
Bio-IT World Q&A with Nathan Myhrvold: Big Pharmas Are Dinosaurs
"But what's a Princeton-educated mathematician, UCLA-trained physicist, gourmet chef, and paleontologist doing in biotech? Well, he's already cashed in on his investment in Rosetta Inpharmatics, which was just sold to Merck & Co. Now he runs Intellectual Ventures, which he's loathe to cast as a VC firm despite its name. The difference is it will fund his ideas rather than those of others.
|
|
